Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs HSBC Holdings plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while HSBC Holdings plc trades at $98.48 (market cap $333.00B). The key difference: HSBC Holdings plc is far larger — about 8.3× Alnylam Pharmaceuticals, Inc.'s market cap, and HSBC Holdings plc pays a 3.78% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HSBC | |
|---|---|---|
Market Cap | $39.89B | $333.00B |
Sector | Health | Technology |
52-Week High | $491.22 | $99.09 |
52-Week Low | $278.09 | $61.30 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
HSBC trades at $99.09, up 1.09% today and near its 52-week high of $99.47. The stock shows bullish technical signals with consistent earnings beats in recent quarters. Recent news highlights strategic moves, including a potential Turkey business sale and AI expansion with Google Cloud. Revenue is stable at $71.02B for 2025, with a net income margin of 30.81% and a P/E ratio of 16.38.
Outlook is cautiously optimistic, supported by earnings momentum and restructuring efforts. Risks include regulatory penalties and global economic sensitivity. Analysts are mixed, with 38.1% recommending buy. The dividend of $0.50 per share adds income appeal, but investors should monitor execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
